MX2015014892A - Method for a cell-based drug screening assay and the use thereof. - Google Patents

Method for a cell-based drug screening assay and the use thereof.

Info

Publication number
MX2015014892A
MX2015014892A MX2015014892A MX2015014892A MX2015014892A MX 2015014892 A MX2015014892 A MX 2015014892A MX 2015014892 A MX2015014892 A MX 2015014892A MX 2015014892 A MX2015014892 A MX 2015014892A MX 2015014892 A MX2015014892 A MX 2015014892A
Authority
MX
Mexico
Prior art keywords
cell
screening assay
time
drug screening
based drug
Prior art date
Application number
MX2015014892A
Other languages
Spanish (es)
Other versions
MX366369B (en
Inventor
Simone Rizzi
Guillaume Jacot
Matthias Lutolf
Original Assignee
Qgel Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qgel Sa filed Critical Qgel Sa
Publication of MX2015014892A publication Critical patent/MX2015014892A/en
Publication of MX366369B publication Critical patent/MX366369B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

The present invention relates to a cell-based drug screening assay comprising the steps of: (i) culturing a cell population in a culturing environment, (ii) defining at least two monitoring points in time in dependency of at least one of the cell types, physiological characteristics of the cells, physiological characteristics of formed-tissue, the mode of action of a drug substance and the culturing environment, (iii) applying drug substances to the cultured cells at least at one treatment point in time, (iv) monitoring of the effect of said drug substance on cells or formed tissues at least at said two monitoring points in time.
MX2015014892A 2013-04-25 2014-04-22 Method for a cell-based drug screening assay and the use thereof. MX366369B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165419.6A EP2796873A1 (en) 2013-04-25 2013-04-25 Method for a cell-based drug screening assay and the use thereof
PCT/EP2014/058152 WO2014173907A1 (en) 2013-04-25 2014-04-22 Method for a cell-based drug screening assay and the use thereof

Publications (2)

Publication Number Publication Date
MX2015014892A true MX2015014892A (en) 2016-03-07
MX366369B MX366369B (en) 2019-07-05

Family

ID=48326111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014892A MX366369B (en) 2013-04-25 2014-04-22 Method for a cell-based drug screening assay and the use thereof.

Country Status (14)

Country Link
US (1) US20160077081A1 (en)
EP (2) EP2796873A1 (en)
JP (1) JP6484219B2 (en)
KR (1) KR102255944B1 (en)
CN (1) CN105143883B (en)
AU (1) AU2014257584B2 (en)
BR (1) BR112015026601B1 (en)
CA (1) CA2910146C (en)
ES (1) ES2729341T3 (en)
IL (1) IL242172B (en)
MX (1) MX366369B (en)
RU (1) RU2702643C2 (en)
SG (1) SG11201508611WA (en)
WO (1) WO2014173907A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
JP6804438B2 (en) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター An in vivo model of the human small intestine using pluripotent stem cells, and methods for making and using it.
JP2016136848A (en) * 2015-01-26 2016-08-04 富士フイルム株式会社 Chemical evaluating method and chemical screening method
GB201514864D0 (en) * 2015-08-20 2015-10-07 Insphero Ag An in vitro 3D cell culture model-based tumor relapse assay
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
KR101916801B1 (en) * 2016-08-12 2018-11-08 경북대학교 산학협력단 A drug screening method for diseases associated choroidal neovascularization using biomimetic three dimensional in vitro system
IT201600099380A1 (en) * 2016-10-04 2018-04-04 Univ Bologna Alma Mater Studiorum COMPOSITIONS, DEVICES AND METHODS FOR IN VITRO CONTROL OF THE CHEMICAL CELL CROPS MICRO-ENVIRONMENT
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2020071484A1 (en) * 2018-10-05 2020-04-09 国立大学法人名古屋大学 Method for screening for chemical substance, program, control device, and culture observation device
GB201818885D0 (en) * 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
DE60220893T2 (en) * 2001-04-03 2008-03-06 Biocept, Inc., San Diego METHOD AND GEL COMPOSITIONS FOR CAPTIVATING LIVING CELLS AND ORGANIC MOLECULES
AU2005253923A1 (en) * 2004-06-08 2005-12-29 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
ES2401640T3 (en) 2008-09-22 2013-04-23 University Of Zurich Prorektorat Forschung Hanging Drop Plate
WO2010083385A2 (en) * 2009-01-15 2010-07-22 The General Hospital Corporation Compounds for reducing drug resistance and uses thereof
US20110004414A1 (en) * 2009-06-06 2011-01-06 Ceetox, Inc. Method for Predicting Respiratory Toxicity of Compounds
EP2380920A1 (en) * 2010-04-22 2011-10-26 QGel SA Hydrogel precursor formulation and production process thereof
CN103328626B (en) * 2010-10-06 2017-02-08 中外制药株式会社 Cancer stem cell mass and process for production thereof
WO2013039087A1 (en) * 2011-09-12 2013-03-21 国立大学法人 熊本大学 Method for screening for substance

Also Published As

Publication number Publication date
CN105143883A (en) 2015-12-09
EP2989460B1 (en) 2019-03-06
AU2014257584A1 (en) 2015-11-05
CN105143883B (en) 2018-10-23
MX366369B (en) 2019-07-05
KR20160003761A (en) 2016-01-11
CA2910146C (en) 2024-04-09
AU2014257584B2 (en) 2020-05-14
BR112015026601A2 (en) 2017-07-25
JP2016518129A (en) 2016-06-23
CA2910146A1 (en) 2014-10-30
EP2796873A1 (en) 2014-10-29
KR102255944B1 (en) 2021-05-25
ES2729341T3 (en) 2019-10-31
EP2989460A1 (en) 2016-03-02
US20160077081A1 (en) 2016-03-17
BR112015026601B1 (en) 2023-11-21
WO2014173907A1 (en) 2014-10-30
IL242172B (en) 2019-03-31
RU2702643C2 (en) 2019-10-09
RU2015150203A (en) 2017-05-31
SG11201508611WA (en) 2015-11-27
JP6484219B2 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
MX2015014892A (en) Method for a cell-based drug screening assay and the use thereof.
CY1123142T1 (en) IMPROVED METHODS FOR THE PRODUCTION OF POSITIVE CELL THERAPEUTICS
EP4306636A3 (en) Monolayer of pbmcs or bone-marrow cells and uses thereof
NZ765695A (en) Immune cell organoid co-cultures
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
MY171710A (en) Culture medium composition, and method for culturing cell or tissue using said composition
MX2021005777A (en) Selective delivery of material to cells.
TR201904270T4 (en) Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions.
WO2016012544A3 (en) Enhanced reprogramming to ips cells
GB2562396A (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
BR112014028881A2 (en) cell populations, cell bank, methods of obtaining a cell population, methods of identifying a factor, selection methods, methods of providing therapy, hepatocyte populations, and method of obtaining cells.
MX2015018035A (en) Methods for predicting responses to chemical or biologic substances.
RS54525B1 (en) Means and methods for treating dlbcl
CY1120800T1 (en) METHODS AND COMPOSITIONS FOR IN VIVO ACTIVATION OF PANCREATIC BETA CELL FORMATION
MX2022003399A (en) Cellular-based method for determining the potency of defibrotide.
EP3608400A4 (en) Cell population including mesenchymal stem cells, production method therefor, and pharmaceutical composition
MX2015008436A (en) Compositions for permeabilising fixed blood cells and uses thereof.
EP3620529A4 (en) Method for monitoring dynamic changes in cells or substance derived therefrom, and method for classifying cell using same
EP3733838A4 (en) Cell population including adhesive stem cells, method for producing such cell population, and pharmaceutical composition
WO2015034710A3 (en) Human cellular models with biosensors
MX2018005228A (en) An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs.
UA78641U (en) method for predicting the severity of patients with acute pancreatitis
EP2610337A4 (en) Human blood-derived blood cell mass assay using cell coagulation, blood adult stem cells using same, method for expanding progenitor cells, and stem cells produced using the method
WO2015051166A3 (en) Use of cox-3 binding molecules for modulating autophagy
WO2016004250A3 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells

Legal Events

Date Code Title Description
FG Grant or registration